Cavatak: Updated Phase II data

Updated data from 51 evaluable patients with stage IIIc/IV malignant melanoma in the 2-stage, open-label, U.S. Phase II CALM trial showed that intratumoral Cavatak led to irPFS, the primary endpoint, ...